Percentage of royalties as per collaboration.

No definition available.

Name:	biib_PercentageOfRoyaltiesAsPerCollaboration
Namespace Prefix:	biib_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential future milestone payments commitment to third party approximately.

+ References

No definition available.

+ Details

Name:	biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Royalties Payable Period, Post FDA Approval

+ References

No definition available.

+ Details

Name:	biib_RoyaltiesPayablePeriodPostFDAApproval
Namespace Prefix:	biib_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=biib_AlkermesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=biib_VUMERITYMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative and Other Relationships - Alkermes (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative arrangements and non-collaborative arrangement transactions
Inventory and purchase commitment charges		$ 2,109.7	$ 1,805.2	$ 1,955.4
Potential future milestone payments commitment to third party approximately		10,000.0
Research and development		2,501.2	3,990.9	2,280.6
Alkermes
Collaborative arrangements and non-collaborative arrangement transactions
Potential future milestone payments commitment to third party approximately				155.0
Research and development		$ 26.5	32.4	53.5
VUMERITY \| Alkermes
Collaborative arrangements and non-collaborative arrangement transactions
Percentage of royalties as per collaboration	15.00%	15.00%
Royalties payable period, post FDA approval	5 years
Inventory and purchase commitment charges		$ 61.6	$ 12.9	$ 1.6